Profound Medical's (PROF) Sell (E+) Rating Reiterated at Weiss Ratings

Key Points

• Profound Medical's stock has been reaffirmed with a "sell (e+)" rating by Weiss Ratings, indicating continued negative outlook from analysts.
• The company's recent earnings report shows a miss on expectations, with a loss of ($0.52) EPS compared to an estimated ($0.43) and revenue of $2.21 million versus a $4.75 million forecast.
• Profound Medical has a market cap of $166.05 million and a negative return on equity of 89.74%, reflecting challenges in profitability.

Profound Medical (NASDAQ:PROF - Get Free Report)'s stock had its "sell (e+)" rating reissued by equities researchers at Weiss Ratings in a report released on Saturday,Weiss Ratings reports.

Profound Medical Stock Performance

Shares of NASDAQ PROF opened at $5.50 on Friday. The company has a debt-to-equity ratio of 0.11, a current ratio of 8.53 and a quick ratio of 7.07. The stock's fifty day moving average price is $4.95 and its two-hundred day moving average price is $5.27. Profound Medical has a one year low of $3.76 and a one year high of $9.17. The firm has a market cap of $166.05 million, a price-to-earnings ratio of -3.77 and a beta of 0.66.

Profound Medical (NASDAQ:PROF - Get Free Report) last released its earnings results on Thursday, August 14th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.09). The company had revenue of $2.21 million for the quarter, compared to analyst estimates of $4.75 million. Profound Medical had a negative return on equity of 89.74% and a negative net margin of 343.97%. On average, equities analysts forecast that Profound Medical will post -1.12 EPS for the current year.

Institutional Trading of Profound Medical

Several large investors have recently modified their holdings of the stock. Thompson Davis & CO. Inc. grew its holdings in shares of Profound Medical by 3.3% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 210,495 shares of the company's stock worth $1,242,000 after purchasing an additional 6,645 shares in the last quarter. Raymond James Financial Inc. lifted its position in shares of Profound Medical by 5.5% during the 2nd quarter. Raymond James Financial Inc. now owns 941,879 shares of the company's stock worth $5,557,000 after buying an additional 49,000 shares during the last quarter. Ardsley Advisory Partners LP lifted its position in shares of Profound Medical by 11.9% during the 2nd quarter. Ardsley Advisory Partners LP now owns 330,000 shares of the company's stock worth $1,947,000 after buying an additional 35,000 shares during the last quarter. TD Waterhouse Canada Inc. lifted its position in shares of Profound Medical by 36.3% during the 2nd quarter. TD Waterhouse Canada Inc. now owns 56,073 shares of the company's stock worth $342,000 after buying an additional 14,920 shares during the last quarter. Finally, MMCAP International Inc. SPC lifted its position in shares of Profound Medical by 2.1% during the 2nd quarter. MMCAP International Inc. SPC now owns 490,859 shares of the company's stock worth $2,896,000 after buying an additional 10,000 shares during the last quarter. 47.86% of the stock is owned by institutional investors and hedge funds.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.